Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) with a highly heterogeneous but potentially aggressive clinical course. Median survival is around 6 years1. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment, yet the advanced age of MF patients and significant transplant-related mortality limit the applicability of this procedure2.

https://www.bbmt.org/article/S1083-8791(20)30455-9/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - July 23, 2020 Category: Hematology Authors: Juan-Carlos Hern ández-Boluda, Arturo Pereira, Alberto Alvarez-Larran, Ana-Africa Martín, Ana Benzaquen, Lourdes Aguirre, Elvira Mora, Pedro González, Jorge Mora, Nieves Dorado, Antonia Sampol, Valentín García-Gutiérrez, Oriana López-Godino, María Source Type: research